177 related articles for article (PubMed ID: 34273139)
1. Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.
Shi J; Chen G; Wang H; Wang X; Han B; Li K; Wang Q; Zhang L; Wang Z; Cheng Y; He J; Shi Y; Chen W; Luo Y; Wu L; Wang X; Nan K; Jin F; Dong J; Li B; Liu Z
Thorac Cancer; 2021 Sep; 12(17):2345-2351. PubMed ID: 34273139
[TBL] [Abstract][Full Text] [Related]
2. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
[TBL] [Abstract][Full Text] [Related]
4. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
5. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer.
Li L; Liu W; Wang Y; Zhang Q; Chi C; Bai Q; Xu C; Yang R
J Chemother; 2021 Nov; 33(7):492-498. PubMed ID: 33818318
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
[TBL] [Abstract][Full Text] [Related]
9. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
[TBL] [Abstract][Full Text] [Related]
10. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib.
Tang M; Song C; Zhang Y; Xu X; Wang C; Zhang Z; Chen T
Lipids Health Dis; 2021 Nov; 20(1):165. PubMed ID: 34801029
[TBL] [Abstract][Full Text] [Related]
11. Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial.
Shen Y; Lu J; Hu F; Qian J; Zhang X; Zhong R; Zhong H; Chu T; Han B
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1417-1424. PubMed ID: 35482076
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
Cheng Y; Wang Q; Li K; Shi J; Liu Y; Wu L; Han B; Chen G; He J; Wang J; Lou D; Yu H; Wang S; Qin H; Li X
Br J Cancer; 2021 Aug; 125(3):366-371. PubMed ID: 34006926
[TBL] [Abstract][Full Text] [Related]
14. Salvage treatment with anlotinib for advanced non-small cell lung cancer.
Wu D; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
Thorac Cancer; 2019 Jul; 10(7):1590-1596. PubMed ID: 31183998
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).
Jiang S; Liang H; Liu Z; Zhao S; Liu J; Xie Z; Wang W; Zhang Y; Han B; He J; Liang W
Oncologist; 2020 May; 25(5):e870-e874. PubMed ID: 32077550
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
[TBL] [Abstract][Full Text] [Related]
17. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study.
Zhang W; Zhang C; Yang S; Chen Q; Wang C; Guo Q
Future Oncol; 2021 Nov; 17(31):4091-4099. PubMed ID: 34254526
[No Abstract] [Full Text] [Related]
20. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
